Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Low-Dose Fostemsavir Formulations and Food Effect
NCT04757974Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Mar 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fostemsavir in human immunodeficiency virus infection (HIV) (8 arms), sponsored by ViiV Healthcare. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last quantifiable time point at 72 hours, Area under the plasma concentration-time curve extrapolated to infinite time at 72 hours and 1 more. Started Mar 2021; status: completed.
02
Drugs
fostemsavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04757974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04757974.